(Q37950428)

25 August 2017

title

Future treatments for Parkinson's disease: surfing the PD pipeline (English)

1 reference

25 August 2017

1 reference

1

Robert A Hauser

1 reference

25 August 2017

publication date

1 January 2011

1 reference

International Journal of Neuroscience

25 August 2017

published in

1 reference

25 August 2017

volume

121 Suppl 2

1 reference

25 August 2017

page(s)

53-62

1 reference

Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Adenosine, adenosine A 2A antagonists, and Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Adenosine A(2A) receptor antagonist treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Duodenal levodopa infusion for the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Duodenal levodopa infusion in Parkinson's disease--long-term experience

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Safinamide: from molecular targets to a new anti-Parkinson drug

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Improvement of motor function in early Parkinson disease by safinamide

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Neurturin, a relative of glial-cell-line-derived neurotrophic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Subthalamic GAD gene therapy in a Parkinson's disease rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2011.620195

10.3109/00207454.2011.620195

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference